

100 Companies: Longevity in Switzerland



ABCDx



ABCDx (Advanced Brain Companion Diagnostics) is a privately-funded start-up company founded in 2014 by three experienced individuals: Two eminent researchers from the Faculty of Medicine of the University of Geneva and the Vall d'Hebron Research Institute (VHIR) at Vall d'Hebron Hospital, Barcelona. Recognized as key opinion leaders in the field of brain biomarkers, they combine expertise in biomarker discovery, validation and clinical experience. The third founder of ABCDx is an experienced industry and licensing executive with experience in both established and start-up diagnostic and pharmaceutical ventures. Transforming care for patients with brain injury. ABCDx provides powerful new tools for transforming the triage, diagnosis and treatment decision process at the point of care for patients presenting with potential brain injury from stroke and trauma to complications. ABCDx is pioneering the ability to decode the chemical messages of the brain so that brain injury can be detected earlier often before hospitalization and from a single blood drop.

Web site:	abcdx.ch
Number of Employees:	Undisclosed
Founded in:	2014
Based in:	Geneva
Sector:	P3
Total Funding Amount:	\$10.1K

Ability Rehab Solutions



They help people with walking difficulties. Ability offers those with mobility issues a means to effective, simple and affordable gait rehabilitation based on the latest research findings. They are synonymous with innovation and quality. Discover the world of ability – a steadily expanding world. At ability they pursue one goal: Returning the precious good of movement to as many people as possible. They achieve this goal through their technology, expertise, ongoing research and development. And while they continue to grow, make progress and expand, their solutions remain affordable for everyone. Ability opens new doors for patients, therapists and clinics alike.

Web site:	ability-switzerland.com
Number of Employees:	11-50
Founded in:	2010
Based in:	Zurich
Sector:	AgeTech
Total Funding Amount:	\$28.7K

Abionic



Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection. Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.

Web site:	abionic.com
Number of Employees:	11-50
Founded in:	2010
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$27.1M

AC Immune



AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates.

Web site:	acimmune.com
Number of Employees:	51-100
Founded in:	2003
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$117.4M

Adipogen International



AdipoGen Life Sciences, Inc. (AdipoGen) consists of two companies, Adipogen SA (Switzerland) (and its branch office Adipogen AG) and Adipogen Corporation (San Diego, USA). The Corporate headquarters is in San Diego, USA and the Operational headquarters is in Liestal, Switzerland. A motivated team of highly-skilled individuals develops and manufactures new products for the Life Science Research Market in the areas of obesity & diabetes, inflammatory diseases, innate immunity, immunology, immuno-oncology, cancer, stem cell biology and neurodegeneration supporting Immunometabolism & Advanced Inflammation Research. In addition to the antibody (special focus functional antibodies) and protein facilities, AdipoGen owns chemical laboratories, enabling the company to isolate unique natural products and to develop new and innovative small molecules and rare antibiotics. Since 2015 AdipoGen operates under the brand “AdipoGen Life Sciences” internationally. In addition to research reagents, AdipoGen is newly developing products for licensing in new market segments (clinical diagnostics/therapeutics).

Web site:	adipogen.com
Number of Employees:	11-50
Founded in:	2011
Based in:	Liestal
Sector:	P3
Total Funding Amount:	Undisclosed

ADR AC



ADR-AC has longtime expertise in drug hypersensitivity research. In case of adverse drug reactions during pre-clinical stages, phase I - III clinical trials or in post-marketing stages, ADR-AC offers defined risk assessment to analyze and evaluate the immune-stimulatory potential of culprit substances. Their know-how in the field of small chemical molecules as well as biologicals, eg therapeutic proteins and monoclonal antibodies.

ADR-AC has profound expertise in performing in vitro experiments based on human immune cells. Upon your request ADR-AC will propose a panel of tests designed to reveal the immunogenic potential of your drug.

Web site:	adr-ac.ch
Number of Employees:	1-10
Founded in:	2007
Based in:	Bern
Sector:	P3
Total Funding Amount:	Undisclosed

aktiia



aktiia is a Swiss startup founded in May 2018 by Mattia Bertschi (CEO) and Josep Sola (CTO). The team currently counts 12 employees and is located in Neuchatel (Switzerland) and Zurich (Switzerland). aktiia's patented core technology for blood pressure monitoring is based on more than 15 years of pioneering work and over 30 peer-reviewed publications at the Swiss research and technology organization CSEM. aktiia's technology combines common optical sensors and clinically validated software algorithms to measure an individual's blood pressure at the wrist. The technology has been validated through trials in acute and low-acute settings with worldwide acknowledgement of its accuracy.

Web site:	aktiia.com
Number of Employees:	11-50
Founded in:	2018
Based in:	Neuchatel
Sector:	AgeTech
Total Funding Amount:	\$4.1M


Amal Therapeutics



Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. The company uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. Amal Therapeutics SA was founded in 2012 and is based in Geneva, Switzerland.

Web site:	amaltherapeutics.com
Number of Employees:	11-50
Founded in:	2012
Based in:	Geneve
Sector:	P3
Total Funding Amount:	\$45.2M

Amazentis



Amazentis is a life science company that conducts research on medication and nutrition. The company focuses on the development of products that meet the health requirements of the aging population. Their products target the reversal of age-related muscle decline by improving the activity of mitochondria.

Amazentis was founded in 2007 by Pierre Landolt and Patrick Aebischer and is based in Lausanne.

Web site:	amazentis.com
Number of Employees:	1-10
Founded in:	2007
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$8.85M

APR Applied Pharma Research



APR Applied Pharma Research s.a. identifies, develops, manufactures, and licenses healthcare products for patients in various therapeutic areas. The company specializes in the development of oral and topical formulations in various healthcare regulatory areas ranging from Rx and OTC pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. It offers a portfolio of prescription products in various pharmaceutical forms in a range of therapy areas with innovative drug delivery systems; and consumer healthcare products for acute pain, cough & cold, insect repellent, intimate care, legs healthcare, pediatric, pregnancy, and proctology. The company provides products for various therapeutic areas, such as cancer supportive care, CNS (migraine), dermatology, genetic metabolic diseases, gynecology, pain management, proctology, tissue transplantation, and wound management. Its strategic focus is in Europe and the United States, as well as fast growing markets, such as China, Russia, and Latin America.

Web site:	apr.ch
Number of Employees:	11-50
Founded in:	1990
Based in:	Balerna
Sector:	P3
Total Funding Amount:	Undisclosed

Aptissen



Aptissen is a company specialized in the research, development and commercialization of biopolymer-based medical devices. Aptissen's team revolutionized the viscosupplement market with Synolis VA and his patented formulation which combines Hyaluronic Acid and Sorbitol. Synolis VA provides rapid mobility recovery, fast long lasting pain relief associated with excellent safety.

The company was founded in 2013 as a spin-off of ANTEIS. It today distributes its products through a worldwide international distributors' network among more than 50 countries including Europe, South America, Canada, Middle East and Asia for instance. Aptissen considers that the future of treatments for the synovial joints requires effective treatments administered in a single session, providing an improvement in mobility and a fast pain relief, as well as the regeneration of cartilage.

Web site:	aptissen.com
Number of Employees:	11-50
Founded in:	2013
Based in:	Plan-les-ouates
Sector:	P3
Total Funding Amount:	Undisclosed

Asceneuron



Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer's disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer's disease. Due to increasing life expectancy, Alzheimer's disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Web site:	asceneuron.com
Number of Employees:	1-10
Founded in:	2012
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$30M

Atracsys



Atracsys was established in 2004, capitalizing years of research at the Swiss Federal Institute of Technology in Lausanne (EPFL). Its name is an acronym for Advanced Tracking Systems, and that's what Atracsys started out with: developing high-precision optical measurement solutions for medical surgery. In 2007, upon an increasing demand to apply its technological optical expertise in touchless interaction and multi-touch systems, Atracsys created a new department called Interactive Solutions.

Atracsys solutions combine utmost measurement accuracy, speed and reliability. Atracsys technology is entirely designed, engineered, manufactured and verified in Switzerland and follows the ISO 13485 medical quality system.

Web site:	atracsys.com
Number of Employees:	11-50
Founded in:	2004
Based in:	Puidoux
Sector:	P3
Total Funding Amount:	Undisclosed

Auris Medical



Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus and restore balance.

Auris Medical is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear. They have two projects in advanced clinical development, Keyzilen® for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. In addition, they have AM-125 in early clinical development for the treatment of vertigo.

Company has additional projects under development and are further strengthening their pipeline through collaborations with leading academic institutions in this field.

Web site:	aurismedical.com
Number of Employees:	11-50
Founded in:	2003
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Axovant Sciences



Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates to comprehensively address the cognitive, functional, and behavioral aspects of dementia. Vision of the company is to become the leading company focused on the treatment of dementia by broadly addressing multiple forms of this condition through developing innovative new medicines for patients.

Web site:	axovant.com
Number of Employees:	51-200
Founded in:	1905
Based in:	Basel
Sector:	Regenerative Medicine
Total Funding Amount:	\$55M

Bacoba

The Bacoba is a young Swiss pharmaceutical company that developed on the basis of unique natural substances innovative new therapeutics. Their diverse research uses the chemical diversity of the living world, traditional medical knowledge, molecular pharmacology, computer-based drug development and synthetic medicinal chemistry to develop novel drugs for the treatment of infectious diseases that are currently insufficiently treatable.

Bacoba has it`s own vision to develop innovative therapeutics derived from the unique chemicals nature supplies. In their multifaceted research they incorporate natural chemodiversity, traditional medicinal knowledge, molecular pharmacology, computer-aided drug design, and synthetic medicinal chemistry, to develop novel drugs for unmet medical needs in the field of infectious diseases.

Web site:	grow-waedenswil.ch
Number of Employees:	Undisclosed
Founded in:	2004
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

BalOnco



BalOnco, founded in 2009, is a Swiss BioPharmaceutical company dedicated to develop innovative medicines in areas of high Medical need, in particular in Oncology and Women's Health. BalOnco has partnered with leading Academic institutions, thus efficiently combining basic research and drug development expertise.

Web site:	balonco.com
Number of Employees:	1-10
Founded in:	2009
Based in:	Kaiseraugst
Sector:	P3
Total Funding Amount:	Undisclosed

Basilea Pharmaceutica



Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the integrated research, development and commercial operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and nonresponse to current treatment options.

Their portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in development. Basilea Pharmaceutica Ltd is building on it`s potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation.

Web site:	basilea.com
Number of Employees:	201-500
Founded in:	2000
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Biocartis



Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnosics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.

Web site:	biocartis.com
Number of Employees:	201-500
Founded in:	2007
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$366.3M

BioVersys



The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company's award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it is possible to restore the efficacy of approved antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital acquired infections) and Tuberculosis.

In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate for the treatment of multidrug-resistant tuberculosis.

Web site:	bioversys.com
Number of Employees:	1-10
Founded in:	2008
Based in:	Basel
Sector:	P3
Total Funding Amount:	\$7.8M

BioXpress Therapeutics



BioXpress creates biosimilars of uncompromising quality. They develop in Switzerland and manufacture for distribution worldwide.

BioXpress was founded in Geneva by the industry leaders in cell-line development and analytical characterization and has built a team of experts in the development of biopharmaceuticals and biosimilars, their manufacturing, characterization, clinical and regulatory development. The company's partnership with Selexis ensures highest standards in cell-line development, coupled with a collaboration with SGS for analytics, and priority access to laboratories and a CMO in Switzerland for optimal process development and GMP manufacturing so that the development of their biosimilars can be managed in a cost-effective and streamlined process.

Web site:	bioxpress.com
Number of Employees:	1-10
Founded in:	2010
Based in:	Plan-les-ouates
Sector:	P3
Total Funding Amount:	Undisclosed

Cardiola



Cardiola AG was founded in 2000 in Winterthur (Switzerland) as CardioRest AG with the singular goal of developing a completely new approach to treating heart failure based on Muscular CounterPulsation research.

m.pulse® is currently the only non-invasive therapeutic system in the world able to treat heart failure not only in hospitals but also on an outpatient basis and even by patients themselves at home. After having actually been awarded a brand new device class, m.pulse® constitutes a completely new market segment.

Web site:	cardiola.ch
Number of Employees:	1-10
Founded in:	2000
Based in:	Winterthur
Sector:	P3
Total Funding Amount:	\$6M

Cardioentis



Cardioentis AG, a biopharmaceutical company, develops drug therapies for the treatment of acute heart failure and related cardiovascular diseases. The company develops TRUE-AHF (TRial of Ularitide's Efficacy and safety in patients with Acute Heart Failure), an ularitide, which is an intravenous infusion treatment for acute heart failure; and SIRIUS I and II, a safety and efficacy study of an intravenous placebo controlled randomized infusion of ularitide in a prospective double-blind study in patients with symptomatic and decompensated chronic heart failures. Its disease-based technology platform includes protein biology to identify novel targets; and design small molecule compounds and peptides for healthcare markets. The company was founded in 2010 and is based in Zug, Switzerland.

Web site:	cardioentis.com
Number of Employees:	Undisclosed
Founded in:	2010
Based in:	Zug
Sector:	P3
Total Funding Amount:	\$118.4M

Cell Receptor



Cell Receptor develops a future-oriented therapy for high medical needs: cancer and autoimmune diseases. Cell Receptor is a small Geneva based startup company, aiming to establish a new option in the treatment of cancer and autoimmune diseases:

The Cell Receptor team has since 2010 been actively engaged in research on cell proliferation and possesses unique knowledge of a very basic control mechanism of cell growth in the body, that was previously unknown and therefore has not been the subject of therapeutic efforts.

Cell Receptor has also knowledge of groups of pharmacological substances able to interfere with this mechanism, and has, basing thereupon, developed a new method for the prevention of cancer metastases. The treatment has the potential to inhibit cancer metastasis at very reasonable costs.

Web site:	cellreceptor.ch
Number of Employees:	Undisclosed
Founded in:	2010
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

CELLEC Biotek



CELLEC BIOTEK is a biotechnology startup that develops and commercializes bioreactors for 3D cell culture and tissue generation. CELLEC BIOTEK is a biotechnology startup that develops and commercializes bioreactors for 3D cell culture and tissue generation. Its team is comprised of an international team of engineers, biotechnologists, and clinicians.

CELLEC BIOTEK's products supports growing 3D living tissues, as advanced model systems for tissue development and drug testing, applied to life sciences and pharmaceutical research, and potentially as biological grafts for tissue and organ regeneration, applied to clinical translation in regenerative medicine.

CELLEC BIOTEK was founded in 2011 and is based in Basel, Basel-Stadt. It is a spin-off of a lab of University Hospital Basel, Switzerland, active in the world of tissue engineering and regenerative medicine.

Web site:	cellecbiotek.com
Number of Employees:	1-10
Founded in:	2011
Based in:	Basel
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Cellestia Biotech



Cellestia is a bio-pharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signaling pathway. Cellestia is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders.

Cellestia Biotech was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne, Switzerland). Cellestia's pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decades of research in Prof. Radtke's laboratory at Swiss Institute for Experimental Cancer Research (ISREC) at EPFL. Prof. Freddy Radtke is an internationally recognized key opinion leader in NOTCH pathway and cancer stem cells research. Dr. Rajwinder Lehal, CSO, has established Cellestia's drug discovery platform and leading the early development phase of the program for a decade.

Web site:	cellestiabiotech.com
Number of Employees:	1-10
Founded in:	2014
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$28M

CeQur



CeQur SA is dedicated to developing and commercializing advanced insulin delivery systems that make it easier for people living with type 2 diabetes to comply with therapy and stay in control of their disease.

CeQur is developing the CeQur Insulin Infuser, a simple and discrete insulin delivery tool for people who could benefit from intensive insulin therapy but want flexibility and freedom from multiple daily injections.

CeQur was established in January 2008 as a spin out from Danfoss A/S, a large, global Danish industrial products group.

Web site:	cequrcorp.com
Number of Employees:	51-100
Founded in:	2008
Based in:	Luzern
Sector:	P3
Total Funding Amount:	\$156.6M

Ciliatech

CILIATECH

Ciliatech is the research, development, production, acquisition and distribution of pharmaceutical and diagnostic products and technologies. The purpose of the Ciliatech is the research, development, production, exploitation, acquisition and distribution of pharmaceutical and diagnostic products and technologies. The company may acquire, hold and dispose of any intellectual property rights or licenses of any kind.

Web site:	ciliatech.com
Number of Employees:	1-10
Founded in:	2011
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Clinerion



Clinerion enables early patient access to innovative treatment through solutions for clinical trial patient search, RWE, & market access. Clinerion accelerates clinical research and medical access to treatments for patients. They use proprietary technologies for analysis of patient data from the global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Their technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. Company creates innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion's proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations.

Web site:	clinerion.com
Number of Employees:	11-50
Founded in:	2008
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

codiag



codiag is a research-driven company that builds softwares to augment doctors and improve patient outcome. codiag provides AI and big data driven real-time matching of patient medical files with virtually every documented disease to support diagnostics, prevention, administration, automation, legal and cost control in hospitals, clinics, GP practices and healthcare related service providers.

codiag is a research-driven company that offers integration of its patent-pending, CE-certified platform ""codiag+Pro"" into existing EHR or other health-data systems.

codiag+Pro processes text-based patient medical files in multiple languages and can produce diagnostic guidance explained by peer-reviewed biomedical literature, patient readmission warnings and other key insights. codiag+Pro can be easily and seamlessly integrated into on-site IT systems as well as off-site patient data storages without the use of specialized AI hardware.

Web site:	codiag.com
Number of Employees:	1-10
Founded in:	2018
Based in:	Zurich
Sector:	P3
Total Funding Amount:	Undisclosed

Corporate Health Solutions



Corporate Health Solutions offers products and services for the analysis and optimization of the team climate and the work situation. Corporate Health Solutions (CHS) GmbH is a spin-off of the University of Zurich (UZH) founded in 2014. They offer products and services for the analysis and optimization of the team climate and the work situation .

As a spin-off of the "Public & Organizational Health" department of UZH, they have extensive research and implementation know-how in the area of work, health and organization.

Their products and services are both scientifically sound and practicable .They are closely networked with companies, associations, universities and management consultants. For the technical solutions, they have a partnership with IT experts from the University of St. Gallen / ETH Zurich.

Web site:	chsolutions.ch
Number of Employees:	1-10
Founded in:	2014
Based in:	Zurich
Sector:	P3
Total Funding Amount:	Undisclosed

Covagen



Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.

Their goal is to access novel biology for each product candidate. Covagen's lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.

In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen's drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech and others.

Web site:	covagen.com
Number of Employees:	11-50
Founded in:	2007
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	\$106M

CovalX



CovalX develops and manufactures scientific instrumentation for academic research and industrial use. CovalX AG was founded in 2006. The company's vision is to become a leading provider of technology and services in the field of protein interaction analysis based on mass spectrometry. With support offices in Switzerland, France and USA, CovalX is a global company offering leading product and services for major pharmaceutical companies as well as academic laboratories. CovalX High-Mass systems and services are sold worldwide through direct offices (Europe, USA) or distributors (China, Japan, Korea). CovalX is a fast growing company, developing innovative analysis solutions for the characterization of therapeutic proteins and protein interactions for the life science industry.

Web site:	covalx.com
Number of Employees:	11-50
Founded in:	2006
Based in:	Zurich
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Covalys Biosciences



Covalys Biosciences AG develops products that help researchers in academic institutions and pharmaceutical and biotech companies to improve the efficiency of research into proteins and their function. Its SNAP-tag technology is a protein tag that covalently links itself to any chemical probe and is provided as a substrate. The company's ACP-tag allows site-specific labeling of proteins on cell surfaces. The company was founded in 2002 and is based in Witterswil, Switzerland.

Web site:	Undisclosed
Number of Employees:	1-10
Founded in:	2002
Based in:	Witterswil
Sector:	Regenerative Medicine
Total Funding Amount:	\$4.8M

Crisalix



Crisalix is the inventor of a 3D, web-based simulator for plastic surgery. Crisalix aims to develop scientific technologies in the field of plastic and aesthetic surgery to improve surgeon-patient relationships. Thanks to its unique solution available on the Internet, Crisalix offers practitioners new consultation standards.

Crisalix is the inventor of e-Stetix, the first web-based 3D preview technology for plastic surgery based on physical properties of the body. As a pioneer in its field, Crisalix has developed a system for reconstructing the patient's body in 3D from 2D images. Spin-off of internationally renowned academic R&D centers such as the Institute of Surgical Technology and Biomechanics (ISTB) of the University of Bern (Switzerland) and Ecole Polytechnique Federale de Lausanne (EPFL - Switzerland), Crisalix was initiated in 2006 with the support of CO-ME network (Computer Aided and Image Guided Medical Interventions) in Switzerland. In 2008, Crisalix started collaborating with ISTB, EPFL and the Department of Plastic and Reconstructive Surgery of the Inselspital Bern. In 2009 the Innovation Promotion Agency (CTI) Switzerland, decided to co-finance Crisalix for its unique technology and for being the pioneer in the field of surgery.

Web site:	crisalix.com
Number of Employees:	51-100
Founded in:	2008
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	Undisclosed

CT Atlantic



CT Atlantic AG is a biotech company focused on the identification and development of human-derived monoclonal antibodies – HD-MABs™ as novel therapeutics for the treatment of cancer. CT Atlantic is a spin-off of the University of Zurich (Zurich, Switzerland) and the Ludwig Institute for Cancer Research (LICR) (Zurich, Switzerland and New York, USA) and has a strong focus on clinical research and applications in the field of oncology. It was founded by Prof. Alexander Knuth, Chairman of the Department of Clinical Oncology at the University of Zurich and one of the pioneers in cancer immunotherapy. He was previously Professor for Oncology at the Klinikum Nordwest (Frankfurt, Germany) and University of Frankfurt, Germany. Prior to this he led the clinical trials and research activities in the Ludwig Institute for Cancer Research, New York and its affiliate in the Krankenhaus Nordwest.

In addition, it has built a network of clinicians and clinical institutions that are closely allied with the Ludwig Institute for Cancer Research, the University of Zurich and Krankenhaus Nordwest (Frankfurt, Germany).

Web site:	ct-atlantic.com
Number of Employees:	1-10
Founded in:	2008
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	\$9M

Cureab



Cureab is a swiss based biotech company that was founded in 2012.

Cureab is focussed on research in inflammation and oncology. Cureab develops therapeutic antibodies from target identification to clinical testing. Two monoclonal antibodies are in late stage pre-clinical development. Cureab welcomes new partnerships with academia and industry.

Web site:	cureab.ch
Number of Employees:	Undisclosed
Founded in:	2012
Based in:	Riehen
Sector:	P3
Total Funding Amount:	Undisclosed

CyanoGuard



Cyanoguard AG is a chemical technology company specialised in the development of novel toxin detection methods to improve environmental monitoring, food safety and health care in remote settings and locations.

Its innovative technology enables fast and safe cyanide detection in food, waste water and other samples. Its method is selective and requires no special training and/or equipment.

Equipped with the latest research, and with over six years of close collaboration with leading industry partners, the company is dedicated to resolve today's cyanide issues, offering fast and safe toxin detection in any setting at any time.

Web site:	cyanoguard.com
Number of Employees:	1-10
Founded in:	2016
Based in:	Wädenswil
Sector:	P3
Total Funding Amount:	Undisclosed

diagene laboratories



diagene laboratories inc. is a worldwide operating company (GmbH) in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. Diagene laboratories inc. is organized under two divisions, Routine Laboratories and Research Laboratories, with offices in Switzerland and Germany.

Founded in 1999, diagene is leading in the diagnostics of familial forms of high cholesterol (familial hypercholesterolemia, familial-defective apolipoprotein B-100, familial dysbetalipoproteinemia, familial combined hyperlipidemia, etc.). Besides a large series of genetic analyses, diagene offers also biochemical and daily routine laboratory analyses. Recently, several new gene test have been introduced, one of them for the prediction, of severe side effects of antiretroviral treatment of patients with HIV, another for the diagnosis of the long qt syndrome.

Web site:	diagene.ch
Number of Employees:	501-1000
Founded in:	1999
Based in:	Reinach
Sector:	P3
Total Funding Amount:	Undisclosed

Dividat



Dividat develops evidence based training concepts to improve mobility in older adults for prevention and rehabilitation. Dividat is a Spin-off company from the ETH Zurich and develops evidence based training concepts to improve mobility in older adults for prevention and rehabilitation. As a spin-off company of ETH Zurich, their solutions are inspired by recent research articles. On a regular basis, their solutions are evaluated in field trials under consideration of the guidelines of international scientific journals.

Web site:	dividat.com
Number of Employees:	1-10
Founded in:	2013
Based in:	Schindellegi
Sector:	P3
Total Funding Amount:	Undisclosed

Dorphan



Dorphan is a preclinical stage drug development company. Dorphan S.A. was founded in 2011 by the members of the Swiss Sanfilippo Foundation in order to discover and pursue the development of drug candidates for orphan and rare genetic diseases. The company R&D activities are built on worldwide innovative research to identify, evaluate and develop preclinical molecules and deliver promising drug candidates to patients.

Web site:	dorphan.com
Number of Employees:	2-10
Founded in:	2011
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	Undisclosed

ecogenics



ecogenics is the leading trusted partner for microsatellite marker development and genotyping projects. ecogenics proudly looks back onto 14 years experience of serving customers in various fields of molecular biology. Founded as a spin-off company from the University of Zurich, ecogenics successfully managed to establish a good reputation for being a reliable partner and providing high quality services.

ecogenics provides comprehensive molecular marker development, and at the same time related services such as genotyping. Their goal is satisfied customers who retain confidence in their products and services in the long run. With most of their customers (research institutes and private companies worldwide) they have recurring projects or long-lasting collaborations.

Web site:	ecogenics.ch
Number of Employees:	Undisclosed
Founded in:	2001
Based in:	Balgach
Sector:	P3
Total Funding Amount:	Undisclosed

Ennar Pharma

The purpose of the Ennar Pharma is the research and development of products for the treatment of psoriasis as well as the consultation, manufacture, distribution and trade of developed products for the treatment of psoriasis. The company can use processes and patents. Ennar Pharma may enter into any kind of business and enter into contracts that are conducive to the purpose of the Company or directly or indirectly related thereto. The Company may participate in, or associate with, other companies. The Company may acquire, hold or sell real estate. It may set up branches and agencies in Germany or abroad by resolution of the Board of Directors.

Web site:	Undisclosed
Number of Employees:	Undisclosed
Founded in:	2010
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Evasensor



Evasensor Ltd. is focused on bringing advanced and affordable biosensor systems to the market for rapid testing at the point-of-use. Evasensor Ltd. is a company focused on bringing advanced and affordable biosensor systems to for OEM-customers to the market for rapid testing at the point-of-use.

The technology offered by Evasensor fulfills the need for rapid, sensitive biochemical testing. For biochemical analysis, the advanced optical reader instruments can be placed directly at the point-of-use and enable decentralized biochemical testing at any place where needed by any person. This offers optimal, cost-effective workflow in research, quality control and analytical laboratories and – most important – after only a few manipulation steps the results are available within 10 minutes.

Web site:	evasensor.com
Number of Employees:	1-10
Founded in:	2010
Based in:	Neuchatel
Sector:	AgeTech
Total Funding Amount:	Undisclosed

ExCellness Biotech



ExCellness provides non-degradable tissue culture surfaces with the elasticity of human tissue, ranging from the stiffness of bone to the softness of brain. Culturing your cells on their adapted culture substrates makes them "FEELING AT HOME"! ExCellness Biotech was incorporated in 2009 as a spin-off project from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. ExCellness maintains close contact with the EPFL research competencies but is also actively collaborating with the University of Toronto (UoT), Ontario, Canada to further develop elastic substrates to culture cells in biomimetic conditions.

Web site:	excellness.com
Number of Employees:	1-10
Founded in:	2009
Based in:	Lausanne
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Exquiron Biotech



Exquiron is dedicated to contract research in early stage drug discovery. Exquiron Biotech is dedicated to state-of-the-art hit identification and validation services for its customers. With a combined team track record of over 60 years in early stage drug discovery and a high level of expertise and flexibility, they help their customers advance their programs and generate added value in the areas of pharmaceutical drug discovery and nutraceuticals.

Web site:	exquiron.com
Number of Employees:	11-50
Founded in:	2013
Based in:	Reinach
Sector:	P3
Total Funding Amount:	Undisclosed

Fasteris



Fasteris is a Swiss biotechnology company based in Geneva. Since 2007, Fasteris developed a broad range of applications to analyze genomes and transcriptomes, from library preparation to bioinformatics analyses: whole genome sequencing, de novo assembly; targeted re-sequencing and exomes; transcriptomes, directional stranded mRNA protocols; small RNAs; CHIP-SEQ to study protein-DNA binding sites; metagenomics; custom projects such as Trypanosoma splice leader, phage display, etc. Fasteris provides services for research laboratories, from small-scale projects to thousands of samples using automated protocols. Since 2013, Fasteris joined the Medisupport Network and produced many thousands of NGS analyses under medical diagnostics conditions for the prenatal diagnostics test Prendia.

Web site:	fasteris.com
Number of Employees:	11-50
Founded in:	2003
Based in:	Plan-les-ouates
Sector:	P3
Total Funding Amount:	Undisclosed

Frimorfo



Frimorfo is a preclinical Contract Research Organization (CRO) located in Marly (Fribourg), Switzerland. Frimorfo offers its expertise on a worldwide basis to pharmaceutical industry, biotechnology firms and universities. As a small and focused company, Frimorfo is in a unique position to play a significant role as a product and service supplier in the discovery and evaluation of novel genes, ultimately leading to the development of new diagnostic and therapeutic approaches.

Frimorfo has established itself as a respected, reliable partner providing high quality products and services and continuously expanding its portfolio. The company provides those kind of services like efficacy studies of drug candidates and phenotyping genetically modified mice.

Web site:	frimorfo.com
Number of Employees:	Undisclosed
Founded in:	1998
Based in:	Fribourg
Sector:	P3
Total Funding Amount:	Undisclosed

Gene Signal



Gene Signal is a research based biotechnology company specialized in the discovery, development, and commercialization of a new class of oligonucleotides, proteins and monoclonal antibodies to treat a range of conditions where angiogenesis plays a determinant role. Gene Signal's innovative therapies use precisely targeted angiogenic (inducing vascular growth) or angiostatic (inhibiting vascular growth) agents, derived from genes that are exclusively involved with the angiogenesis process.

Gene Signal's therapies aim to provide a more targeted alternative to existing solutions like Vascular Endothelial Growth Factors which impact other physiological phenomena in addition to angiogenesis. Gene Signal's targeted therapies represents a novel, next-generation approach to the management of angiogenesis based conditions and offer the potential to improve treatment options for concerned patients.

Web site:	genesignal.com
Number of Employees:	11-50
Founded in:	2000
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	Undisclosed

Genedata



Genedata is a bioinformatics company that specializes in developing software systems for the comprehensive analysis of genomes, transcriptomes, proteomes, metabolomes, and biochemical compounds and uses sophisticated computational solutions for related research processes in the life sciences. By working closely with key partners, the company combines its extensive product portfolio with expert scientific consulting services to offer tailor-made solutions for specific applications and multiple therapeutic areas. The company's solutions are key for moving the focus of life science research from high-throughput data acquisition to high-content data interpretation.

Web site:	genedata.com
Number of Employees:	51-100
Founded in:	1997
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Genentech



Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline.

The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech's Research and Early Development section operates as an independent center within Roche.

Web site:	gene.com
Number of Employees:	10001+
Founded in:	1976
Based in:	Basel (Roche), San Francisco, CA, USA (Subsidiary)
Sector:	Regenerative Medicine
Total Funding Amount:	\$1.64B

Geneva Biotech Center



Geneva Biotech Center responds to the growing trend of pharmaceutical companies outsourcing research and development capabilities and acquiring projects in more advanced stages.

Consequently, the GBC operates as a pre-pharmaceutical company: collaborating with selected partners to develop promising and innovative molecules, to be licensed to a pharmaceutical company for their commercialization. The Geneva Biotech Center is composed of a group of business and scientific experts passionate about their work, each with more than twenty years of experience, mainly in research and development in the pharmaceutical industry. The GBC selects promising projects, builds a de-risked development path according to pharmaceutical quality standards, and offers optimal development and valorization to its academic, commercial and financial partners.

Web site:	genevabiotechcenter.com
Number of Employees:	2-10
Founded in:	2013
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

Genkyotex



Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Web site:	genkyotex.com
Number of Employees:	11-50
Founded in:	2006
Based in:	Geneve
Sector:	Regenerative Medicine
Total Funding Amount:	\$81.8M

GenomSoft



GenomSoft is a Swiss company located at the Campus Biotech EPFL Innovation Park in Geneva, a state-of-the-art hub hosting companies and institutions working on biotechnology and life science projects.

GenomSoft's team is composed of engineers and entrepreneurs with an extensive experience in research, development, and project management of high-end domains and industrial segments, such as digital signal processing, telecommunications, information security and avionics.

They are developing a new set of software tools, derived from the digital-media industry, in order to provide every organization working with genomic data with enterprise-grade technologies and devices able to store, transport and process genomic information in compliance with MPEG-G, the new ISO standard for genomic information representation.

Web site:	genomsoft.com
Number of Employees:	2-10
Founded in:	2017
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

GenomSys



GenomSys is a Swiss company composed by engineers with extensive experience in research, development and project management in high-end domains and industrial segments such as digital signal processing, telecommunications, information security and avionics. Their experience spans from embedded software and firmware for low-power devices to hard real-time programming in safety-critical environments up to the design and integration of desktop and server applications in the digital multimedia and telecommunications market.

All the engineers are extensively accustomed to the ISO process of standardization, with experience in development and normative editing of audiovisual coding, systems and conformance testing standards. GenomSys develops technology powering a new generation of tools and devices for the efficient compression, storage, transport and manipulation of genomic data in compliance with MPEG-G, the new ISO standard for genomic information representation.

Web site:	genomsys.com
Number of Employees:	1-10
Founded in:	2016
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	Undisclosed

Gnothis



Gnothis represents a unique source of knowledge within the field of molecular medicine. Gnothis was founded year 2000 by Professor Rudolf Rigler as well as a gremium of leading scientists, supported by institutional as well as private investors. The company covered two operational units: Gnothis AB, Kista, Sweden, and Gnothis SA, Lausanne, Switzerland. During the years 2000-2003 these operational units developed the Direct Gene expression Analysis (DGA) application and made considerable research and development concerning single-molecule DNA sequencing.

In June 2003 a strategic partnership was initiated with Evotec Technologies GmbH, Hamburg, Germany. The purpose of the partnership with Evotec Technologies GmbH is to enable a full scale commercialization of Direct Gene expression Analysis (DGA).

Web site:	gnothis.com
Number of Employees:	1-10
Founded in:	2000
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	Undisclosed

Gondola Medical Technologies



Gondola Medical Technologies is a Swiss company specialized in research and the development of new technologies in the fields of physiotherapy, neurological and osteoarticular rehabilitation. It has developed and brought to the market the GONDOLA™ medical device to give the AMPS treatment, a non-invasive add on therapy to treat motor symptoms in Parkinson's Disease; symptoms that best respond to the GONDOLA™ treatment are Freezing of Gait, walking, slowness of movement and balance.

The GONDOLA™ device has been designed to be used at home; its use requires few minutes, and benefits remain for a period ranging from 3 to 5 days. Regular use of the device twice a week allows to maintain benefits overtime.

Web site:	gondola-parkinson.com
Number of Employees:	1-10
Founded in:	2011
Based in:	Lugano
Sector:	AgeTech
Total Funding Amount:	Undisclosed

GTX medical



GTX medical was founded in December 2014, splitting off from the Swiss federal institute of technology Lausanne (EPFL) to specifically develop a new neurostimulation therapy. Company is based at the High-Tech Campus in Eindhoven, Netherlands, and at the Technical and Life Science Faculties of EPFL, Lausanne, Switzerland. Both sites are locations where world class research is developed, and they are proud to continue in this tradition.

Based on years of research by Professor Grégoire Courtine at EPFL CNP, company have developed an advanced therapy to help people with paraplegia recover the strength and ability to once again use their legs. Using a targeted neuro-stimulation implant with real-time motion feedback, combined with bodyweight support assisting training tools, our technology has the potential to restore the function of the spinal cord and improve the rehabilitation of individuals with SCI. Company calls this approach Targeted Epidural Spinal Stimulation (TESS). The therapy allows remodeling of neural pathways, repairing the connection between brain, spine, and lower extremities – with the potential of improving other symptoms related to spinal cord injuries.

Web site:	gtxmedical.com
Number of Employees:	11-50
Founded in:	2014
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$40M

healthbank innovation




healthbank, a health-related data transaction platform, allows people across the globe to exchange health data in a secure & compliant way. healthbank is the world's first people-owned, neutral and independent health data transaction platform that empowers people across the globe to exchange their health data in a secure and compliant way.

healthbank connects data sources from all facets of the healthcare ecosystem and rewards participants for sharing their data for research purposes. Based in Switzerland, healthbank leverages Swiss neutrality, trust and data privacy to enable citizen users, researchers and organizations with large data sets to unlock the value of health and medical data on its independent, global transaction platform. By doing so, healthbank drives innovation in health sciences, from prevention to cure, at a better price with better quality for the benefit of both the individual and society.

Web site:	healthbank.coop
Number of Employees:	1-10
Founded in:	2011
Based in:	Baar
Sector:	P3
Total Funding Amount:	\$6.27M

Humabs



HUMABS BioMed
a subsidiary of Vir Biotechnology

Humabs, a subsidiary of Vir Biotechnology, is an antibody therapeutics biotechnology company based in Switzerland spin-off from the Institute of Biomedical Research (IRB), Bellinzona, with which Humabs has a strong collaborative relationship. The Company is focused on discovering and developing fully human monoclonal antibodies to treat serious infections. Humabs has proprietary discovery technologies – CellClone – that were utilized successfully to advance from discovery to lead compounds in only a few months. The CellClone technology platforms enable the isolation of antibodies that have passed natural selection by the human immune system in response to infectious diseases and can generally be further developed without extensive lead optimization.

Humabs has a portfolio of more than a fifteen immunotherapy product candidates, some addressing large markets and others against orphan diseases, which, while small in terms of patient numbers, have high morbidity and mortality rates.

Web site:	humabs.com
Number of Employees:	11-50
Founded in:	2004
Based in:	Bellinzona
Sector:	P3
Total Funding Amount:	Undisclosed

IDUN Technologies



Developing meaningful wearable devices with great user experience together with strong partners. IDUN Technologies Ltd. is an electrode company based in Zurich, Switzerland, founded in November 2017. Based on work done in a collaboration between the bioelectronics and micro- and nanosystems research groups at the ETH Zurich, IDUN is developing and producing soft and dry conductive electrodes for biopotential monitoring (ECG, EEG, EMG).

They are focusing on business-to-business partnerships with device manufacturers. Their technology is compatible to user's unique device architecture and will increase the impact of your recordings. IDUN offers a range of electrode designs for client's application. Bioinspired adhesion mimicking grasshopper feet, skin conformal soft electrodes for brain wave, heart and muscle monitoring belong to the core competences. The company's emphasis is on products that are unobtrusive in daily life and offer sufficient signal quality for various data analysis tools. Get in contact to find out more about their EEG, ECG and EMG electrodes.

Web site:	iduntechnologies.ch
Number of Employees:	1-10
Founded in:	2017
Based in:	Zurich
Sector:	AgeTech
Total Funding Amount:	\$130K

IFPMA



IFPMA is involved in the discovery of and access to life-saving and life-enhancing medicines & vaccines for people everywhere. At IFPMA they advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere. IFPMA represents research-based biopharmaceutical companies, and regional and national associations across the world. The company facilitates collaboration, dialogue, and understanding within its industry and with other global players in the health community.

IFPMA brings the industry and broader health community together to foster innovation, promote resilient regulatory systems and high standards of quality, uphold ethical practices, and advocate sustainable health policies to meet global needs. IFPMA is the unique, informed, and credible voice in conversation with the global health community to address the many challenges in public health policy for current and future generations.

Web site:	ifpma.org
Number of Employees:	11-50
Founded in:	1968
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

InPheno



Precisely Swiss - InPheno AG, Basel provides quality services in drug discovery. The company strives to be the one-stop solution for clients needs in research and profiling of drug candidates. InPheno offers to act as an extension of clients drug development team, partnering small virtual biotech companies or large pharmaceutical organizations.

The high rate of contract renewals may serve as indicator for their customer's high confidence in the InPheno's services. InPheno's founding team consists of specialists in the fields of virology and oncology with long-term experience in the pharmaceutical industry. The company's scientists combine a broad expertise in molecular and cellular assay technology as well as in the development of modern therapeutics.

Web site:	hosteurope.ch
Number of Employees:	1-10
Founded in:	2001
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

iOnctura



iOnctura is a late stage preclinical biotechnology company developing a pipeline of next generation, best-in-class molecules for the treatment of cancer and fibrosis.

iOnctura is developing a pipeline of carefully selected assets. Programs in oncology aim to harness both immune-mediated and direct anti-tumour activity to deliver superior clinical efficacy in monotherapy or combinations. By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

Web site:	ionctura.com
Number of Employees:	1-10
Founded in:	2017
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

Juvaplus




Juvaplus was founded by Bernard-Pierre Legrand in 2011. Specializing in the design and production of compact and wireless motorized devices, Juvaplus quickly imposed itself as a leading innovative company in the medicine market. Juvaplus develops products that combine research, design and technology at the service of medicine. Based in Neuchâtel, Switzerland, their offices are located inside the brand new NEODE Innovation Park.

JUVAPLUS worked closely with EPFL (the Swiss Federal Institute of Technology in Lausanne) for the development of its technology, while receiving support from the Swiss Confederation. EPFL is the most cosmopolitan research university in Europe and is ranked amongst the best universities in the world. With numerous publications, inventions and patents under its belt, EPFL is an ideal partner to guide research works at JUVAPLUS.

Web site:	juvaplus.com
Number of Employees:	11-50
Founded in:	2011
Based in:	Neuchatel
Sector:	AgeTech
Total Funding Amount:	Undisclosed

Kuros Biosciences



Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore's Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland.

Web site:	kuros.ch
Number of Employees:	11-50
Founded in:	2000
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	\$70.9M

Leucogenics

The purpose of the Leucogenics is the research, development and marketing of immunosuppressive therapies and diagnoses. Leucogenics may acquire, manage and sell real estate as well as any business directly or indirectly related to the purpose of the Company. The company also participates in other, domestic or foreign companies of all kinds.

Web site:	Undisclosed
Number of Employees:	Undisclosed
Founded in:	2009
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Mackenzie Innovations



Mackenzie Innovations provides external research, development and product innovation specialized in the areas of biomedical engineering and nanotechnology. In other words, they discover, they create, they solve and they invent and/or improve medical devices, sensors and systems, in partnership with customers or independently. At present Mackenzie Innovations is a sole proprietorship, owned and operated by Dr. Robert MacKenzie. Although not a pure social enterprise, Mackenzie Innovations does consider the health of people and the planet, in addition to profit, in its core business strategy. Recognized as an spin-off company of the ETH Zurich.

Web site:	mackenzieinnovations.com
Number of Employees:	0-1
Founded in:	2010
Based in:	Zurich
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

MaxWell Biosystems



MaxWell Biosystems AG provides solutions to advance basic neuroscience research and accelerate preclinical drug discovery. MaxWell Biosystems develops and markets advanced electrophysiology platforms for cell assays in preclinical drug discovery, safety pharmacology and basic neuroscience research. MaxOne (single-well) and MaxTwo (multi-well) allow stimulation and recording of every active cell on a dish at unprecedented spatio-temporal resolution. These instruments will advance and accelerate drug discovery and basic neurosciences.

Cell types: Neurons, cardiomyocytes, induced pluripotent stem cell (iPSC), others. Preparations: acute brain slice and retina, dissociated cell culture, organotypic slice culture, embryoid body. Applications: phenotype screening, detailed single cell analysis, multi-parametric network analysis, drug efficacy testing, toxicity testing

Web site:	mxwbio.com
Number of Employees:	11-50
Founded in:	2016
Based in:	Basel
Sector:	P3
Total Funding Amount:	\$102K

Meierhofer



Meierhofer has been one of the leading solution providers for digital patient care in the German-speaking market for more than 30 years. Right from the start, their focus is on supporting their customers on their way to digitization so that they can concentrate on their medical and nursing skills. They focus specifically on hospitals, clinics and hospitals in Germany, Austria and Switzerland. They owe this approach to their healthy, continuous growth and stability that is exceptional to the healthcare industry, giving their clients a high degree of investment security.

They support health care institutions with the consistently interoperable and process-oriented approach of their entire portfolio. Their solutions can not only be combined with each other, but above all integrated into existing IT infrastructures - both in individual areas as well as the entire organization. In doing so, they strive to advance networking, both at ward level within the hospital and across sectors, to the integration of care and research.

Web site:	meierhofer.com
Number of Employees:	11-50
Founded in:	1998
Based in:	Liebefeld
Sector:	AgeTech
Total Funding Amount:	Undisclosed

Memo Therapeutics



Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual's B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual's immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Web site:	memomab.com
Number of Employees:	1-10
Founded in:	2012
Based in:	Zurich
Sector:	P3
Total Funding Amount:	\$3.3M

Memocare



In the fight against dementia, one of the most threatening diseases of our times, new chances and perspectives arise in the early detection, diagnosis and treatment. In close collaboration with the University of Zurich memocare AG transfers findings of scientific research into the development of innovative medical technology, applications and services.

Web site:	memocare.com
Number of Employees:	Undisclosed
Founded in:	2011
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	Undisclosed

MIAC



Since 1995, MIAC has been committed to deliver fully-personalized data analysis for pharmaceutical and academic research. The Medical Image Analysis Center (MIAC) is a clinical research organisation supporting international trials with advanced image acquisition and analysis technologies. As an academic corporation that was founded at the Basel University Hospital in 1995, MIAC today is tightly embedded in a national and international institutions and research network, driving the translation of novel imaging and post-processing modalities from development to application in clinical trials.

A highly specialized team of board-certified neuro-/radiologists, physicists, biomedical engineers, IT specialists, technicians and clinicians deliver tailor-made image data analysis services and international trial support to the leaders of the pharmaceutical industry. All MIAC services follow the high standards of Swiss quality and comply with the requirements of FDA – 21 CFR Part 11 & ICH – Good Clinical Practices.

Web site:	miac.swiss
Number of Employees:	11-50
Founded in:	1995
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

NBE-Therapeutics



NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors. NBE-Therapeutics GmbH engages in the development of antibody drug conjugates for the therapy of cancer.

Web site:	nbe-therapeutics.com
Number of Employees:	Undisclosed
Founded in:	2012
Based in:	Basel
Sector:	P3
Total Funding Amount:	\$43M

Nebion



Nebion is a Swiss company founded by an interdisciplinary group of scientists. The goal of NEBION is to support drug discovery, translational biology and personalised medicine research in academia and industry by curating, integrating and mining molecular data on a very large scale. Nebion currently commercializes GENEVESTIGATOR®, the premier gene expression search engine used by over 75'000 researchers world-wide.

Over more than a decade, they have continuously perfected techniques and vocabularies for the biocuration of biological experiments. Their unique collections of deeply curated and high quality transcriptomic data, combined with their high-performance but easy-to-use tools, enable global and instant analysis of the world's transcriptomic data for novel discoveries and for validation.

Web site:	nebion.com
Number of Employees:	11-50
Founded in:	2008
Based in:	Zurich
Sector:	P3
Total Funding Amount:	Undisclosed

Neurimmune Holding



Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs.

With its unique Reverse Translational Medicine™ platform, Neurimmune creates recombinant human-derived monoclonal antibodies with biophysical characteristics closely resembling those occurring in healthy elderly. These antibodies display unique properties such as target selectivity, superior pharmacodynamics and low immunogenicity, resulting in superior risk profiles and excellent efficacy.

Neurimmune's pipeline comprises programs for a broad variety of disease related targets and specific target conformations. These include misfolded, oligomeric, fibrillar or post-translationally modified forms of disease-associated proteins as well as physiological conformations involved in major disease pathways.

Web site:	neurimmune.com
Number of Employees:	1-10
Founded in:	2006
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	\$150M

Novartis



Novartis researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction.

Web site:	novartis.com
Number of Employees:	10001+
Founded in:	1895
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

OncoEthix



Oncoethix SA is a private Swiss company that was founded in 2007 by Esteban Cvitkovic, MD, Kay Noel, PhD, Yves Paternot, and Patrice Herait, MD (all former associates at Cvitkovic & Associates Consultants SA) to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization.

Since its founding, Oncoethix has in-licensed three promising cancer drug candidates, each a first-in-class agent to a novel target or with a novel mode of action. Currently, two portfolio compounds are in clinical development.

Oncoethix was launched with an initial financing of 1.30 million Swiss francs from the founders to finance portfolio development. In December 2009, the company closed a Series A financing of 3.7 million Swiss francs with leading venture capital firms Index Ventures and Endeavour Vision.

Web site:	oncoethix.com
Number of Employees:	Undisclosed
Founded in:	2007
Based in:	Lausanne
Sector:	P3
Total Funding Amount:	\$24.08M

Photoderma




PhotoDerma SA is a development stage company engaged in research and development of novel cosmetics and pharmaceuticals as well as of related medical devices in the field of photodynamic therapy (PDT) and photodiagnosics. It is a spin-off of the photomedicine group of the Swiss Federal Institute of Technology in Lausanne (EPFL) and has been founded in May 2003 by private shareholders and the EPFL.

The main focus of PhotoDerma SA's activity lies on applications of photodynamic therapy (PDT) for cosmetic and therapeutic applications in dermatology. The company also carries out research mandates in various segments of PDT and photodiagnosics.

PhotoDerma SA has active collaborations with the Swiss Federal Institute of Technology in Lausanne (EPFL) and the University Hospitals of Geneva (HUG) and Lausanne (CHUV).

Web site:	photoderma.com
Number of Employees:	Undisclosed
Founded in:	2003
Based in:	Ecublens
Sector:	P3
Total Funding Amount:	Undisclosed

PIQUR Therapeutics



PIQUR Therapeutics AG is a clinical-stage pharmaceutical company that manufactures and markets cancer therapeutics. The company focuses on the discovery and development of anti-cancer drugs based on phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin inhibition (mTOR). PIQUR Therapeutics AG was founded in 2011 and is based in Basel, Switzerland.

Web site:	piqur.com
Number of Employees:	11-50
Founded in:	2011
Based in:	Basel
Sector:	P3
Total Funding Amount:	\$86.9M

Pregnolia



Pregnolia AG is a medical device startup based in Zurich. Their company is at the stage of clinical development. They focus on the development and commercialization of a diagnostic device to identify women at risk for preterm delivery early in pregnancy such that gynecologists can make key decisions about preterm birth management. It is their mission to reduce the number of premature babies worldwide.

Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete the clinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.

Web site:	pregnolia.com
Number of Employees:	1-10
Founded in:	2015
Based in:	Zurich
Sector:	AgeTech
Total Funding Amount:	\$3.6M

Prexton Therapeutics



Prexton Therapeutics has the mission to develop innovative drugs to improve the quality of life.

Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson's disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson's disease.

Web site:	prextontherapeutics.com
Number of Employees:	1-10
Founded in:	2012
Based in:	Geneve
Sector:	P3
Total Funding Amount:	\$41.1M

Roche



Roche Holding AG is the owner of F. Hoffmann-La Roche Ltd., a provider of in-vitro diagnostics and drugs for cancer and transplantation. It specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. F. Hoffmann-La Roche Ltd. serves hospitals, research labs, private medical labs, practicing physicians, and patients.

Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. F. Hoffmann-La Roche Ltd., also conducts research and development as well as production related to molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostics and research.

F. Hoffmann-La Roche Ltd was established in 1896 and is based in Basel, Switzerland.

Web site:	roche.com
Number of Employees:	10001+
Founded in:	1896
Based in:	Basel
Sector:	P3
Total Funding Amount:	\$2.7B

Roche Diagnostics



Roche Diagnostics GmbH manufactures instruments and reagents for genome sequencing, microarray analysis, nucleic acid purification, real-time PCR, and cell analysis. It offers sequencing, PCR/RT-PCR, sample preparation, cell biology, and discovery reagent solutions for cancer research, cellular analysis, gene expression, gene knockdown, protein expression, and bio-processing/manufacturing applications. The company also provides resources to support the life science community, including online technical and application information, on-site product supply programs, and technical and customer service; and specialty bio-chemicals for industrial applications and custom manufacturing. It offers its products online. Roche Diagnostics GmbH was formerly known as Boehringer Mannheim GmbH and changed its name to Roche Diagnostics GmbH in January 1999. The company was founded in 1859 and is based in Mannheim, Germany. Roche Diagnostics GmbH operates as a subsidiary of Roche Holding AG.

Web site:	roche-diagnostics.co.in
Number of Employees:	Undisclosed
Founded in:	1988
Based in:	Basel
Sector:	P3
Total Funding Amount:	Undisclosed

Roche Glycart



Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

Areas of operating include: Glycart's detailed financings; Comprehensive pipeline breakdown, including molecular targets & partnerships. The company has 17 years of in-depth BioPharma industry analysis.

Web site:	roche.ch
Number of Employees:	11-50
Founded in:	2000
Based in:	Schlieren
Sector:	P3
Total Funding Amount:	\$13.6M

RodanoTech



RodanoTech is a Swiss based CRO specialised in clinical Data Management services and EDC solutions. RodanoTech provides effective strategies and solutions that meet the unique needs of the post-approval market, including Phase IV studies, Registries and online Medical Communities. They provide solid Data Management and EDC services. They build Investigator focused Clinical Trial solutions. They setup your online Medical Community platform. They provide creative e-Solutions for the post-approval Market.

RodanoTech highly skilled DM team provides comprehensive Data Management and eCRF design services to the pharma industry and CROs as well as academic research organisations. They assist you with any size study, from small Phase I studies to large-scale trials involving sophisticated designs and long-term follow-up across clinical settings and geographies. They work in collaboration with your preferred CRO or one of their partner CROs to combine the full range of services needed for the execution of your study.

Web site:	rodanotech.ch
Number of Employees:	1-10
Founded in:	2007
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

Scailyte



A new and emerging type of analytical devices produce rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.

Scailyte AG addresses this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying algorithms allow them to associate patterns in single-cell data with disease status, similar to how state-of-the-art methods for object recognition associate pixel patterns with objects. They provide a software solution (ScaiVision), wrapping the AI technology for R&D customers from academia, pharmaceutical and clinics.

Additionally, through their ScaiBioMarker Discovery service, by partnering with pharmaceutical & biotechnology companies they provide special single-cell technology and expertise for novel biomarker discovery, which will yield ultra-sensitive biomarkers for early and precise detection of a wide range of complex diseases.

Web site:	scailyte.com
Number of Employees:	1-10
Founded in:	2017
Based in:	Sursee
Sector:	P3
Total Funding Amount:	\$2.76M

Sensometrix



Sensometrix is a limited liability security company founded in Geneva (Switzerland) in 2006 by Nicolas Rebetez and Adrien de Loës.

Sensometrix brings biometrics for a convenient and secure daily usage.

Sensometrix brings you the next generation of biometrics technologies. Convenience, speed and security form the bedrock of their product offering. Sensometrix products are leveraging years of research and development and enable competitive advantages such as system simplicity, seamless performance and high reliability. With a growing network of global partners, Sensometrix operates internationally in the following sectors: healthcare, banking / retail, education.

Web site:	sensometrix.ch
Number of Employees:	11-50
Founded in:	2006
Based in:	Geneva
Sector:	P3
Total Funding Amount:	Undisclosed

SonoView



SonoView is a Swiss company founded by Dr. Ivana Jovanovic Balic in 2010 as a spin-off from Ecole Polytechnique Fédérale de Lausanne (EPFL). It is located at the Swiss Innovation Park in Biel – an innovation hub for application-oriented research and development.

SonoView is developing an advanced 3D ultrasound imaging technology for early and more accurate diagnosis of breast cancer.

Specialties: ultrasound imaging, temperature monitoring with acoustic tomography, 3D/4D ultrasound image reconstruction, development of new ultrasound scanners, inverse problems, advanced signal and image processing, nonlinear tomography, beamforming, and time delay estimation.

Web site:	sono-view.com
Number of Employees:	1-10
Founded in:	2010
Based in:	Nidau
Sector:	P3
Total Funding Amount:	Undisclosed

Stemmedica International



Stemmedica International S.A. was founded in 2008 as a global, biotechnology company that explores therapeutic applications of patented stem cells to treat degenerative diseases. In 2012 the Swiss Commission for Technology and Innovation (CTI) awarded Stemmedica International and the Laboratory of Biomedical Optics at the École Polytechnique Fédérale de Lausanne (EPFL) a grant to develop practical applications of stem cell therapies and brain imaging for Alzheimer's disease. Stemmedica International has an exclusive rights to manufacture and apply Stemmedica's allogeneic, ischemia-tolerant mesenchymal (itMSC) and neural (itNSC) stem cell lines and stem cell factors to create therapies for the treatment and prevention of Alzheimer's disease and vascular dementia. The company also has Swissmedic licenses to import, export and distribute Stemmedica's cell lines worldwide for human use in approved clinical trials. Stemmedica's stem cell lines have a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. Manufactured in compliance with cGMP, the technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union.

Web site:	stemmedica-intl.com
Number of Employees:	Undisclosed
Founded in:	2008
Based in:	Lausanne
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Straumann



Straumann conducts research, develops and manufactures dental implants, instruments, prosthetics, as well as dental biomaterials for use in tooth replacement and restoration, or to prevent tooth loss.

As technological advancements are changing dentistry fundamentally, Straumann offers a broad range of products and solutions for both conventional treatment and digital workflows including guided surgery, intra-oral scanning and CAD/CAM restorations.

Web site:	straumann.com
Number of Employees:	5001-10000
Founded in:	1954
Based in:	Basel
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Swiss Cardio Technologies



Swiss Cardio Technologies supports Research, Development and Commercialisation of Health focused ideas, in particular in the field of Cardiovascular Medicine.

Swiss Cardio Technologies, by connecting academy and industry, is in an ideal position to evaluate medical innovations. They provide personalized strategies to convert research results into commercial reality, without impairing academicians' needs. They are committed to support and promote academic R&D while promoting ethics, integrity and respect regarding human being and environment.

Web site:	swisscardiotech.com
Number of Employees:	Undisclosed
Founded in:	2008
Based in:	Stansstad
Sector:	P3
Total Funding Amount:	Undisclosed

Swortec



Established in 2004, SWORTEC was formed in collaboration with the Swiss Foundation of Cyberthosis (FSC) and as a result of extensive scientific research work previously undertaken at the Federal Institute of Technology in Lausanne (EPFL). The FSC is an interdisciplinary Research & Development institute in the field of neurotechnologies, specialising in neurological re-education, particularly for paraplegic and hemiplegic patients.

Their Cyberthosis product line consists of innovative devices and methods. The first stationary device MotionMaker™ and its accessories has been launched on the market in 2008 and has been successfully employed at online gambling sites with real money three different rehabilitation and research institutions in Switzerland.

Another important milestone in the enhancement of SWORTEC product portfolio is the development of a mobile and autonomous vertical device WalkTrainer™, the launch of which is planned for 2011.

Web site:	swortec.ch
Number of Employees:	Undisclosed
Founded in:	2004
Based in:	Monthey
Sector:	AgeTech
Total Funding Amount:	Undisclosed

TOLREMO Therapeutics



TOLREMO has created ground-breaking scientific knowledge that allows it to pursue its passion to discover and develop novel targeted therapeutics that will meaningfully extend the lives of patients suffering from cancer.

TOLREMO therapeutics AG (“TOLREMO”) is a privately held research-stage biotechnology company. TOLREMO was founded in March 2017 as an ETH Spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin, and Emmanuel Savioz (MBA). The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug resistance therapies.

Web site:	tolremo.com
Number of Employees:	1-10
Founded in:	2017
Based in:	Zurich
Sector:	P3
Total Funding Amount:	\$11.4M

TransCure bioServices



TransCure offers pre-clinical contract research services to pharmaceutical, biotech, start-up and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed animal models with functional humanized systems have been developed to provide predictive in vivo pharmacology testing in the field of inflammation, and autoimmune (IBD, RA, SLE, MS), anti-infective (HIV, EBV, CMV, Dengue), vaccine development, biosimilar and preclinical lead candidate selection / validation for drug development.

Their customer-oriented approach includes co-designing of experiments with customers to match their needs, diligently and carefully performing the ordered studies and providing comprehensive data analysis and reporting. They are also committed to the 3R principles “reduce, refine and replace” and carefully design the experiments to refine and reduce the use of experimental animals. Located in France, near Geneva, their state-of-the-art animal facilities (BSL 2&3) and scientific programs are ready to serve customers around the world for their faster access to market entrance.

Web site:	transcurebiosciences.com
Number of Employees:	1-10
Founded in:	2012
Based in:	Carouge
Sector:	P3
Total Funding Amount:	\$1.07M

Vivendy Therapeutics



Vivendy Therapeutics Ltd. engages in the development of an enzyme replacement therapy for Morbus Morquio, a rare lysosomal storage disease based on a gene deficiency.

The company was founded in 2006 and is based in Basel, Switzerland.

Web site:	vivendy.ch
Number of Employees:	1-10
Founded in:	2006
Based in:	Basel
Sector:	Regenerative Medicine
Total Funding Amount:	Undisclosed

Xigen



Xigen is a privately-owned biopharmaceutical company founded in 2002 as a spin-off from the University Hospital of Lausanne (CHUV) that specializes in the development of peptides for use against inflammation. Xigen's peptides have high stability and specificity. They are selectively delivered to their intracellular targets through proprietary carrier molecules. The company's lead compound, XG-102, is a D-amino-acids peptide, highly selective, non-competitive, long-acting inhibitor of c-jun N-terminal kinase (JNK). Xigen's second JNK inhibitor lead compound, namely XG-104, is a L/D-amino-acids peptide.

Xigen business model is based on the development and commercialisation of new therapeutic peptides through partnerships with pharma companies.

To achieve this goal, Xigen's approach is to surround itself with dedicated and recognized professionals and international experts in drug development and inflammation in order to reach the demonstration of safety and clinical efficacy of drug candidates in the most expedite way.

Web site:	xigenpharma.com
Number of Employees:	11-50
Founded in:	2002
Based in:	Epalinges
Sector:	P3
Total Funding Amount:	\$41M

Xsensio



Xsensio develops the unique Lab-on-Skin™ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about their health and wellness, in a simple and non-invasive way.

The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developed at the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, their sensing platform unleashes a whole new set of possibilities in continuous health monitoring.

Web site:	xsensio.com
Number of Employees:	1-10
Founded in:	2014
Based in:	Lausanne
Sector:	AgeTech
Total Funding Amount:	\$1.1M

Youdowell



Youdowell is scientifically supported by the University of Basel. Youdowell benefits from a highly skilled tech team and scientific advisory members (University Basel, St. Petersburg State University).

Youdowell's B2C approach: offering personal, flexible and adaptive health coaching plan to optimize client's overall lifestyle balance. Youdowell's B2B approach: offering a holistic and scalable application for health experts to improve their consulting performance towards their clients. They are collecting anonymous health data for scientific research projects. Youdowell's cloud-based application provides REST API for future integrations. It's micro-service architecture allows building custom application configurations for related projects: e.g. University Basel research project: www.movingcall.com.

Web site:	youdowell.com
Number of Employees:	1-10
Founded in:	2009
Based in:	Horgen
Sector:	P3
Total Funding Amount:	Undisclosed

Zeptosens



Zeptosens is an ultra-sensitive microarray platform for quantitative proteomic investigations. It provides microarray platforms for sensitive and quantitative protein profiling, and signaling pathway analysis by reverse protein arrays. Its products include ZeptoREADER, a microarray reader for Zeptosens planar wave-guide technology; ZeptoMARK protein microarray chips and ZeptoCARRIER for various data points, which are split into arrays. The company also offers protein array services, including protein profiling for various samples, such as cell lines, tissues, microdissected cells, and depleted serums; and assay development.

In addition, it provides training services, technical and applications support, and technical service and maintenance. The company's products are used in various applications, including biomarker/target discovery and validation, cell-based screening, mode of action profiling, selectivity profiling, and toxicology investigation. Its customers include pharma research and development companies, biotech companies, and academic institutions.

Zeptosens was founded in 1998 and is headquartered in Wilderswil, Switzerland.

Web site:	zeptosens.com
Number of Employees:	1001-5000
Founded in:	1998
Based in:	Wilderswil
Sector:	Regenerative Medicine
Total Funding Amount:	\$14M